Bristol Myers details Krazati confirmatory study failure in colorectal cancer

Data ReadoutnegativeKrazatiNegative

AI Analysis

Summary

Bristol Myers Squibb announced that a confirmatory trial for Krazati failed to meet its objectives in colorectal cancer patients when combined with an EGFR inhibitor.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Confirmatory trial for Krazati failed in colorectal cancer

Importance:7/10

Sentiment:

-0.80

clinical trial failureoncologycolorectal cancer

Related Companies

$BMY

Read the original article

Published by Endpoints News on July 6, 2026 2:59 PM

Read Original